People with multiple system atrophy and progressive supranuclear palsy had the shortest life expectancy, with a mortality rate that was more than 3 times higher than for the general population.
Requip and Requip XL are non-ergot dopamine agonists indicated for the treatment of Parkinson disease.
Inbrija is the first and only FDA-approved inhaled levodopa for intermittent treatment of OFF episodes in patients with Parkinson disease taking carbidopa/levodopa.
Age at Parkinson disease onset is independently associated with the performance of executive functions.
Patients with idiopathic parkinsonism have reduced survival, although survival is dependent on the type and characteristics of the parkinsonian disorder.
The normal human appendix seems to contain pathogenic forms of α-synuclein, which may impact the risk for developing Parkinson disease.
Patients with both Parkinson disease and type 2 diabetes were more likely to have cardiovascular comorbidities than those with only Parkinson disease.
Participants in the RBD group had significantly worse performances on the Symbol Digit Modality Test compared with participants in the hyposmia and NMC cohorts.
Gout may be associated with a higher risk for incident PD in older adults.
One in two women and one in three men will develop dementia, stroke, or parkinsonism during their lifetime.
The open-label safety study included patients from 3 Gocovri dyskinesia efficacy trials (N=223) and evaluated the long-term safety and tolerability of the treatment.
In order to determine the risk of PD associated with various β2‐adrenoreceptor drugs, the study authors assessed United States Medicare beneficiary data from 2009.
A greater proportion of patients with dysautonomia had supine hypertension compared with patients without dysautonomia.
Based on the data, the FDA has concluded that the drug's benefit continues to outweigh its risks for patients with hallucinations and delusions associated with Parkinson's disease psychosis.
Kinase inhibition or allele-specific targeting of mutant LRRK2 may still be a meaningful target for therapeutic development.
A sensor array has the potential to identify de novo Parkinson's disease (PD) patients with high sensitivity, specificity, and accuracy values.
The studies that included neurocognitive measures demonstrated no significant difference between the use of rTMS and sham-rTMS.
Mutations in the LRP10 gene appear to be common in patients with inherited α-synucleinopathies.
Investigators sought to determine whether patients with moderate to advanced Parkinson disease have impaired glucose levels during an Oral Glucose Tolerance Test.
The Parkinson's Foundation Prevalence Project estimates that within the next 2 years, 930,000 people in the United States will be living with the condition; that number is anticipated to rise to 1.2 million by 2030.
Investigators sought to determine if the ECAS diagnostic screening tool is sufficiently sensitive to distinguish between progressive supranuclear palsy and Parkinson disease.
Study investigators enrolled a total of 37 patients with PD who had participated in a larger prospective, controlled exercise study.
Nuplazid, a non-dopaminergic, selective serotonin inverse agonist, targets 5-HT2A receptors that are thought to be involved in Parkinson's disease psychosis.
There is an increased rate of subsequent Parkinson disease among individuals diagnosed with type 2 diabetes mellitus.
For patients with Parkinson disease, dopamine agonist use is associated with incidence of impulse control disorders in a dose-effect relationship.
A total of 42 consecutive patients with PD who underwent STN-DBS were enrolled in this study.
Sunovion announced that the FDA has accepted the NDA for apomorphine sublingual film to treat motor fluctuations seen in patients with Parkinson's.
Investigators tested functional connectivity between the right and left hypothalamus as well as the other brain regions by using the seed-to-voxel strategy.
The Future of Freezing of Gait in Parkinson's: Exploring Potential Treatments and Preventive StrategiesJune 12, 2018
More than half of patients diagnosed with Parkinson disease experience freezing of gait.
Surgical interventions for Parkinson disease are experiencing a swell in innovation, thanks in part to the entry of two additional medical device companies into a field previously dominated by one company.
Neurology Advisor Articles
- Survival in Parkinson Disease Dependent on Parkinsonian Type, Characteristics
- Case Study Report: Herbal Supplement Kratom Associated With Neonatal Abstinence Syndrome
- Mobile Health Apps for Headache: An Ongoing Search for Clinical Relevancy
- Behavioral Therapies May Treat Headache and Post-Concussive Symptoms
- CBD Superior to Placebo, Similar to AEDs for Managing Epilepsy Syndromes
- Alemtuzumab Linked to Clinical and MRI Disease Remission in Multiple Sclerosis
- Very Early Mobilization After Stroke Does Not Improve Survival Over Usual Care
- Levodopa Inhalation Powder Approved for Parkinson Disease
- Hematology Indicates Need for Thrombophilia Test in Children With Migraines
- Increased Stroke Risk Following Surgical vs Transfemoral Aortic Valve Replacement
- Ocrelizumab Reduces Upper Extremity Disability Progression Risk in PPMS
- Cerebellar Stimulation May Help Improve Gait and Balance Recovery in Stroke
- Increased Dementia Risk in Older Adults With Down Syndrome
- Psychotherapy May Reduce Frequency of Nonepileptic Seizures
- Should CHA2DS2-VASc Be Reassessed More Frequently to Improve Stroke Prevention in Afib?